BioSpace News Archive

POINT Biopharma Global Inc. (NASDAQ: PNT), a company accelerating the discovery, development, and global access to life changing radiopharmaceuticals, today released additional preclinical data from its fibroblast activation protein-alpha (FAP-alpha) inhibitor program called PNT2004.

Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today that it will report fourth quarter and fiscal year 2021 financial results on Tuesday, October 12, 2021, before the market open.

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced new 12-month safety data from the pivotal Phase 3 NORSE TWO trial that further confirm the strong safety profile in this study of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for treatment of neovascular age-related macular degeneration (wet AMD).

Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body, announced today the publication of research titled “Peptide-HLA-based immunotherapeutics platforms for direct modulation of antigen-specific T cells” in the peer-reviewed Nature journal, Scientific Reports.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, will present at investor conferences.

As global SARS-CoV-2 research efforts continue, labs are increasingly conducting scientific studies using banked saliva samples, taking advantage of a sample type which is easy to access and non-invasive.

Cartesian Therapeutics, a fully integrated, clinical-stage biopharmaceutical company pioneering RNA cell therapy in and beyond oncology, today announced the hire of Miloš Miljković, M.D., as Vice President and Chief Medical Officer.

Shionogi to Present In Vitro and Real-World Data at IDWeek 2021 Demonstrating Activity of FETROJA ® (cefiderocol) Against Gram-Negative Pathogens

Fact.MR – A Market Research and Competitive Intelligence Provider: As per latest Fact.MR analysis, the global benzodiazepine drugs market is set to register steady growth during the forecast period between 2020 and 2026.

RELIEF THERAPEUTICS Holding SA reported that the parent company of its U.S. collaboration partner, NRx Pharmaceuticals, Inc., has issued a press release announcing top line data demonstrating improved outcomes at one year in highly comorbid patients with COVID-19 who were treated with ZYESAMI /aviptadil).